Tenatumomab

Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach[1][2].

Product Specifications

CAS Number

[1412891-40-7]

Product Name Alternative

ST2146

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tenatumomab.html

Purity

95.0

Solubility

10 mM in DMSO

Smiles

[Tenatumomab]

Molecular Weight

(147.86 kDa)

References & Citations

[1]Giannini G, et al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27 (15) :3248-3253. |[2]De Santis R, et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res. 2006 Apr 1;12 (7 Pt 1) :2191-6.